Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 4.8% - Should You Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report)'s stock price was down 4.8% during trading on Monday . The stock traded as low as $4.19 and last traded at $4.19. Approximately 97,282 shares traded hands during trading, a decline of 97% from the average daily volume of 3,049,515 shares. The stock had previously closed at $4.40.

Analyst Ratings Changes

Several equities research analysts have recently commented on IRWD shares. Leerink Partners started coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They set a "market perform" rating and a $5.00 price target on the stock. Craig Hallum decreased their price target on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, August 9th. Leerink Partnrs raised Ironwood Pharmaceuticals to a "hold" rating in a research note on Monday, September 9th. Wells Fargo & Company decreased their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating on the stock in a research note on Friday, August 9th. Finally, Capital One Financial lowered Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $12.17.

Ironwood Pharmaceuticals Trading Down 4.8 %

The company has a market cap of $655.86 million, a PE ratio of -0.61 and a beta of 0.48. The business has a 50 day simple moving average of $4.46 and a two-hundred day simple moving average of $5.97.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the transaction, the insider now owns 284,661 shares of the company's stock, valued at $1,215,502.47. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 12.90% of the company's stock.

Institutional Trading of Ironwood Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in IRWD. Vanguard Group Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 16,033,545 shares of the biotechnology company's stock worth $183,424,000 after buying an additional 1,137,845 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Ironwood Pharmaceuticals by 152.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 2,645 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in Ironwood Pharmaceuticals by 209.9% in the 1st quarter. Los Angeles Capital Management LLC now owns 85,343 shares of the biotechnology company's stock valued at $743,000 after purchasing an additional 57,806 shares in the last quarter. Hodges Capital Management Inc. acquired a new stake in Ironwood Pharmaceuticals in the 1st quarter valued at $7,521,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Ironwood Pharmaceuticals by 63.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 79,361 shares of the biotechnology company's stock valued at $691,000 after acquiring an additional 30,745 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.